Joseph Famulare is Vice President - Global Quality Compliance and External Collaboration at Genentech/Roche, Pharma Technical Operations. He is active in aligning industry and international...
Biopharmaceutical manufacturing faces many new opportunities as we enter this decade. ISPE is returning to Boston for the 2020 ISPE Biopharmaceutical Manufacturing Conference on 1-3 June 2020, bringing you once again an innovative conference, followed by the 2020 ISPE Continuous Manufacturing Workshop and relevant training classes 4-5 June 2020. The Boston area, including Cambridge, is home to over 1,000 biotechnology companies, leading research, and academic institutions advancing biotechnology medicines.
This year, the 2020 ISPE Biopharmaceutical Manufacturing Conference will focus on advances in manufacturing, facilities, and analytics important to bring new therapies to patients. Now more than ever, manufacturing is on the critical path as many new treatments in the area of personalized medicines and individualized batch production present the challenge to bring these medicines through rapid development, reliable manufacturing, and availability to patients a pace with the advances clinical research is bringing to address unmet needs. At the same time, biosimilars are advancing with the opportunity to provide more access to medicines.
Topics that will be addressed at this conference include:
Session leaders and speakers are top leaders and experts in their fields of industry, regulatory, and/or academia. Topics will cover how we continually improve and manufacture our current processes, and continue to advance into new modalities. At the same time, the sessions will address how conventional norms of manufacturing testing and regulatory GMP and CMC oversight are advancing to meet patient needs.
Keep watching as our agenda advances, with updates from our planning committee. I look forward to seeing you in Boston in June.
In the pharmaceutical industry, disaster recovery is not just about protecting business continuity; it is about safeguarding patient safety, data integrity, and the entire supply chain. The increasing complexity of global pharmaceutical operations exposes companies to a broad spectrum of risks, ranging from man-made disasters such as geopolitical conflicts to natural disasters that can cripple...
ISPE’s Q12 Implementation team, a working group under the auspices of ISPE's Product Quality Lifecycle Implementation (PQLI)® committee, continued their series of training events with a well-attended course delivered to Singapore’s Health Sciences Authority (HSA) in November 2024.